Skip to content

Contact +44 (0) 20 7060 7474 email us

Pfizer

Pfizer

Market Outlook for a Global Leader, 2008-2013

Publication Date August 2008
Publisher Visiongain
Product Type Report
Pages 125
ISBN Number not applicable
Product Code VIS00078

Price

£1,499.00
approximately: $2,234 | €1,644

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Pfizer is the world's largest and most profitable pharmaceutical company.

Its pharmaceutical division generates sales of $44671m in 2007. Pfizer is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. Pfizer's prominence is due to the company having nine blockbuster products, seven market leaders and strong products in all the major therapeutic categories. How can you compete with them? Which areas are the exposed in? Find out today.

This new report - Pfizer - Market Outlook for a Global Leader, 2008-2013 - examines the Pfizer group critically, through comprehensive research and analysis. This report covers both of Pfizer's pharmaceutical and animal healthcare division. Importantly, visiongain discusses Pfizer in the context of the wider pharmaceutical industry and global market. Furthermore, visiongain applied independent analysis and techniques such as financial forecasting, SWOT analyses, R&D pipeline analysis and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report:

In particular, Pfizer - Market Outlook for a Global Leader, 2008-2013 concentrates on the following essential aspects of that company and it s market, including the competitive environment for leading pharma companies:

  • Detailed analysis of Pfizer's divisions and its products, including Lipitor
  • Sales forecasts for Pfizer's pharmaceutical division
  • Sales forecasts for key products and therapeutic areas
  • Discussions of issues affecting the relevant market segments, including competitor analysis
  • Drivers and opportunities for Pfizer
  • Restraints and threats facing the company
  • Discussion of company strategy in the context of the market
  • Pipeline developments and their implications for the future
  • Strategic alliances and licensing
  • International operations, including developing markets.

Visiongain believes that the period 2008 to 2013 will be pivotal for Pfizer, particularly due to patent expiry and the demands of new technological paradigms, such as biologics and genomic medicine. A closer examination of Pfizer's portfolio reveals that many of its leading products will lose patent protection during the next five years, causing severe revenue erosion for the company.

Those challenges include Lipitor, the number-one selling drug in history and a product responsible for a significant share of Pfizer's revenue. The global healthcare industry is entering an exciting new period, with both significant opportunities and great challenges for companies such as Pfizer.

Any professional interested in the fortunes of leading pharmaceutical companies from the present onwards cannot afford to ignore this study.

Contents

  • Chapter 1: Executive Summary
    • 1.1 Pfizer - The Leading Pharmaceutical Company
    • 1.2 A Pivotal Point in Pfizer's Modern History
    • 1.3 Aims, Scope and Format
  • Chapter 2: An Overview of Pfizer and Its Current Positioning in the Global Pharmaceutical Market
    • 2.1 Introduction to Pfizer's Position in the Global Pharmaceutical Market
    • 2.2 Pfizer's History - Becoming One of the Most Successful Pharmaceutical Company
    • 2.3 Pfizer's Business Divisions & Key Personnel
      • 2.3.1 Pfizer's Pharmaceutical Product Division - Its Main Revenue Generating Division
      • 2.3.2 Pfizer's Animal Health Division Contributes a Relatively Small Portion to Pfizer's Total Revenue
      • 2.3.3 Key Personnel
    • 2.4 Pfizer's Therapeutic Area of Interest
      • 2.4.1 Cardiovascular/Metabolic/Endocrine Diseases
      • 2.4.2 Neuroscience
      • 2.4.3 Allergy & Respiratory (A&R)
      • 2.4.4 Inflammation/Arthritis
      • 2.4.5 Pain
      • 2.4.6 Infectious Diseases
      • 2.4.7 Genitourinary/Sexual Health
      • 2.4.8 Oncology
      • 2.4.9 Ophthalmology
      • 2.4.10 Gastrointestinal & Hepatology
    • 2.5 Key Financial Figures 2007
    • 2.6 Pfizer's Top Ten Leading Pharmaceutical Products
    • 2.7 Business Strategies & Company Outlook
  • Chapter 3: Pfizer's Leading Therapeutic Area's Market Forecast, 2008-2013
    • 3.1 Pfizer's Therapeutic Classes - Analysis and Forecasts
      • 3.1.1 The Cardiovascular (CVS)/Metabolic Class is Pfizer's Leading Therapeutic Area
      • 3.1.2 The Central Nervous System (CNS) Class Will Exhibit Strong Growth Throughout the Forecast Period
      • 3.1.3 Infectious/Respiratory Diseases Will Remain As Pfizer's Third Leading Therapeutic Class
      • 3.1.4 Pfizer's Urology Class Will Decline in Revenues
      • 3.1.5 Arthritis/Pain Class Will Show Promising Growth
      • 3.1.6 Pfizer's Oncology Class Will Also Exhibit Positive Growth
      • 3.1.7 Ophthalmology Class Will Show Negative Growth
      • 3.1.8 Pfizer's Endocrinology Class Will Show the Highest CAGR
  • Chapter 4: Pfizer's Leading Pharmaceutical Products - Analysis and Forecasts
    • 4.1 Pfizer's Pharmaceutical Sales Division Will Suffer From Patent Expiries of Key Products During 2007-2013
      • 4.1.1 Pfizer's Top 20 Pharmaceutical Products
    • 4.2 Lipitor, The World's Best Selling Drug, Will Suffer From Patent Expiration
      • 4.2.1 Lipitor's Main Competitors in the Statin Market
      • 4.2.2 Lipitor Will Lose Dominance to Lyrica by 2012
      • 4.2.3 New Analysis on Higher Doses of Lipitor Shows Reduced Cardiovascular Risks in Bypass Surgery Patients
    • 4.3 Norvasc Will Lose Revenue after Loss of Exclusivity in 2007
      • 4.3.1 Norvasc Has Faced Serious Patent Challenges
      • 4.3.2 Norvasc Currently Leads the Calcium Channel Inhibitors Market for Hypertension
    • 4.4 Celebrex Continues to Show Strong Growth - But Will it Last?
      • 4.4.1 Pfizer Starts Celebrex and Bextra Settlements
      • 4.4.2 Study Shows Celebrex Does Not Prevent Memory Loss in the Elderly
      • 4.4.3 Celebrex Currently Leads the Arthritis Market
    • 4.5 Lyrica's New Approved Indication for Fibromyalgia Will Drive Sales
      • 4.5.1 Lyrica Will Become Pfizer's Leading Pharmaceutical Product by 2012
      • 4.5.2 Lyrica Currently Lies Third in the Anti-Seizure Market
    • 4.6 Zyrtec Will Exhibit Negative Growth Throughout the Forecast Period
      • 4.6.1 Zyrtec Currently Leads the Allergic Rhinitis Market
    • 4.7 Viagra Will Gradually Decline in Sales Through, 2008-2013
      • 4.7.1 Viagra Could be used in Muscular Dystrophy
      • 4.7.2 Viagra Will Suffer From Strong Competition in the Erectile Dysfunction Market
    • 4.8 Xalatan/Xalacom Revenues Look Promising Until 2011
      • 4.8.1 Xalatan/Xalacom Leads the Intraocular Drug Market
    • 4.9 Detrusitol/Detrol to Suffer From Patent Expiration in 2010
      • 4.9.1 Detrusitol Leads the Urinary Incontinence Market
    • 4.10 Zeldox/Geodon to Reach Peak Sales of $1377m by 2011
      • 4.10.1 Pfizer's Zeldox/Geodon Faces Strong Competition in the Antipsychotic Market
    • 4.11 Camptosar Will Fall in Revenue During 2008-2013
      • 4.11.1 Camptosar Will Remain Second in the Vinca Alkaloid Market
    • 4.12 Leading Product Summary
  • Chapter 5: SWOT Analysis - Latest News and Key Issues Affecting Pfizer Pharmaceuticals
    • 5.1 A SWOT Analysis for Pfizer, 2008-2013
      • 5.1.1 Important Drivers for Pfizer
      • 5.1.2 Important Restraints for Pfizer
    • 5.2 Key Issues for Pfizer
    • 5.3 The Loss of Patent Protection Will Heavily Affect Pfizer's Revenues
      • 5.3.1 Pfizer Sees Q1 2008 Profits Decline
    • 5.4 Illegal and Counterfeit Drugs
      • 5.4.1 Pfizer's Bid to Tackle Counterfeit Drugs
    • 5.5 FDA - The Threat of Non-Approval, Voluntary Removal from the Market and Increasing Stringency
    • 5.6 Pricing and Reimbursement, Medicare and Cost Controls
    • 5.7 Antibiotic Resistance
    • 5.8 From Blockbuster to Designed Aimed Shots
  • Chapter 6: Pfizer's Business Strategies and Mergers & Acquisitions
    • 6.1 Companies Such As Pfizer Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Market
      • 6.1.1 Reduced Efficiencies in R&D Result in Concerns Over Thinning Pipelines
    • 6.2 Mergers and Acquisitions Give Pfizer Strong Financial Capabilities
    • 6.3 Pfizer Uses Research Alliances Extensively
    • 6.4 Business Strategies and Future Outlook for Global Growth
      • 6.4.1 Pfizer's R&D Prospects
      • 6.4.2 Global Growth Opportunities & New Business Units
      • 6.4.3 Growth Opportunities in Emerging Markets
    • 6.5 Latest Business News
      • 6.5.1 Pfizer to Build $294m Biologics Plant to Develop Novel Drugs
      • 6.5.2 Pfizer Selling Esperion Therapeutics
      • 6.5.3 Pfizer Set to Close its Sterile Manufacturing Plant
      • 6.5.4 Pfizer and Avant Get Regulatory Approval in Cancer Licensing Deal
      • 6.5.5 Pfizer and FivePrime in New Research Deal
    • 6.6 Pfizer's International Strategy - Strong Emphasis on Asian Markets, Especially China
      • 6.6.1 US Market Contributes Most Sales
      • 6.6.2 Pfizer Joins HPIC to Donate Drugs Worth $2.2m to China and Other Countries
  • Chapter 7: Pfizer AH (Animal Health) Business Sector
    • 7.1 Pfizer AH Overview
    • 7.2 Pfizer AH Products and Areas of Interest
    • 7.3 Latest Pfizer AH News
      • 7.3.1 Pfizer AH to Acquire Two Livestock Genomics Companies
      • 7.3.2 Pfizer AH and Schering-Plough in Animal Health Products Deal
      • 7.3.3 Pfizer AH Opens New $47.7m Vaccine Development Centre in Belgium
  • Chapter 8: Pipeline Developments
    • 8.1 Pfizer Has Been Very Active in R&D in Recent Years
    • 8.2 Pfizer Plan Late-Stage Biotherapeutics Programme
    • 8.3 Pfizer Set to Drop Glaucoma Drug
    • 8.4 Pipeline Drugs
      • 8.4.1 Maraviroc
      • 8.4.2 CP 945598
      • 8.4.3 Axitinib
      • 8.4.4 Apixaban
      • 8.4.5 Azithromycin/Chloroquine
      • 8.4.6 CP-675206 (ticilimumab/tremelimumab)
      • 8.4.7 Fablyn (lasofoxifene)
      • 8.4.8 Zeven (dalbavancin)
      • 8.4.9 Toviaz (fesoterodine)
    • 8.5 Pipeline Summary
  • Chapter 9: Conclusions
    • 9.1 Pfizer is Facing a Future of High Revenue Losses
    • 9.2 Patent Loss
    • 9.3 Lipitor May Reduce Generic Loss Through Extra Indications
    • 9.4 Future Direction
    • 9.5 Future Strategy
    • 9.6 Summary
  • List of Tables
    • Table 2.1 Overview of Pfizer's Current Business Divisions, 2007
    • Table 2.2 Pfizer's Key Financials ($m), 2007
    • Table 2.3 Pfizer's Top Ten Pharmaceutical Products, 2007
    • Table 3.1 Revenues ($m) for Pfizer's Leading Therapeutic Classes, 2008-2013
    • Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for Pfizer's Therapeutic Classes, 2007 & 2013
    • Table 3.3 Revenues ($m), Market Share and Growth (%) of Pfizer's Leading Therapeutic Classes, 2007
    • Table 4.1 Pfizer Pharmaceuticals Global Net Sales ($m), 2008-2013
    • Table 4.2 Pfizer Pharmaceuticals 6-Year CAGR (%) and Market Share (%), 2007 & 2013
    • Table 4.3 Pfizer's Pharmaceutical Products Facing Patent Expiry
    • Table 4.4 Pfizer Pharmaceuticals Top 20 Products Worldwide Sales ($m), 2007
    • Table 4.5 Lipitor Revenues ($m), 2008-2013
    • Table 4.6 Top Five Cholesterol Drugs by Revenue ($m), 2007
    • Table 4.7 Norvasc Revenues ($m), 2008-2013
    • Table 4.8 Top Five Calcium-Channel Inhibitors for Hypertension by Revenue, 2007
    • Table 4.9 Celebrex Revenues ($m), 2008-2013
    • Table 4.10 Top Five Arthritis Drugs by Revenue, 2007
    • Table 4.11 Lyrica Revenues ($m), 2008-2013
    • Table 4.12 Top Five Anti-Seizure Drugs by Revenue, 2007
    • Table 4.13 Zyrtec Revenues ($m), 2008-2013
    • Table 4.14 Top Five Allergic Rhinitis Drugs by Revenue, 2007
    • Table 4.15 Viagra Revenues ($m), 2008-2013
    • Table 4.16 Top Five Erectile Dysfunction Drugs by Revenue, 2007
    • Table 4.17 Xalatan/Xalacom Revenues ($m), 2008-2013
    • Table 4.18 Top Five Intraocular Drugs by Revenue, 2007
    • Table 4.19 Detrusitol Revenues ($m), 2008-2013
    • Table 4.20 Top Five Urinary Incontinence Drugs by Revenue, 2007
    • Table 4.21 Zeldox/Geodon Revenues ($m), 2008-2013
    • Table 4.22 Top Five Antipsychotic Drugs by Revenue, 2007
    • Table 4.23 Camptosar Revenues ($m), 2008-2013
    • Table 4.24 Top Five Vinca Alkaloid Drugs by Revenue, 2007
    • Table 5.1 A SWOT Chart for Pfizer, 2008-2013
    • Table 6.1 Share of Pfizer's Pharma Sales (%) by Region, 2007
    • Table 6.2 Share of Pfizer's Pharma Sales (%) by Leading Country, 2007, 2010 and 2013
    • Table 7.1 Breakdown of Pfizer's Business Division ($m), 2003-2007
    • Table 8.1 Summary of Pfizer's Pipeline Drugs from Phase II and Above, 2008
  • List of Figures
    • Figure 2.1 Pfizer's Sales by Business Sector ($m), 2007
    • Figure 2.2 Pfizer's Sales by Therapeutic Class ($m), 2007
    • Figure 2.3 Pfizer's Sales by Geographic Region ($m), 2007
    • Figure 2.4 Pfizer's Top Ten Pharmaceutical Products Revenue ($m), 2007
    • Figure 3.1 Pfizer's Therapeutic Classes Revenue ($m) Comparison, 2007 & 2013
    • Figure 3.2 Therapeutic Classes Market Share (%), 2007
    • Figure 3.3 Therapeutic Classes Market Share (%), 2013
    • Figure 3.4 CVS/Metabolic Class Revenue ($m) Forecast, 2008-2013
    • Figure 3.5 CNS Class Revenue ($m) Forecast, 2008-2013
    • Figure 3.6 Infectious/Respiratory Class Revenue ($m) Forecast, 2008-2013
    • Figure 3.7 Urology Class Revenue ($m) Forecast, 2008-2013
    • Figure 3.8 Arthritis/Pain Class Revenue ($m) Forecast, 2008-2013
    • Figure 3.9 Oncology Class Revenue ($m) Forecast, 2008-2013
    • Figure 3.10 Ophthalmology Class Revenue ($m) Forecast, 2008-2013
    • Figure 3.11 Endocrinology Class Revenue ($m) Forecast, 2008-2013
    • Figure 4.1 Pfizer Pharmaceuticals Overall Net Sales ($m), 2008-2013
    • Figure 4.2 Top 20 Prescription Products vs. the Rest of the Portfolio (%) Contribution of Revenues, 2007 & 2013
    • Figure 4.3 World Revenues ($m) for Lipitor, 2008-2013
    • Figure 4.4 Market Share (%) for Top 5 Cholesterol Treatments, 2007
    • Figure 4.5 World Revenues ($bn) for Norvasc, 2008-2013
    • Figure 4.6 Market Share (%) for Top 5 Calcium-Channel Inhibitors for Hypertension, 2007
    • Figure 4.7 World Revenues ($bn) for Celebrex, 2008-2013
    • Figure 4.8 Market Share (%) for Top 5 Arthritis Treatments, 2007
    • Figure 4.9 World Revenues ($bn) for Lyrica, 2008-2013
    • Figure 4.10 Market Share (%) for Top 5 Anti-Seizure Treatments, 2007
    • Figure 4.11 World Revenues ($m) for Zyrtec, 2008-2013
    • Figure 4.12 Market Share (%) for the Top 5 Allergy Treatments, 2007
    • Figure 4.13 World Revenues ($m) for Viagra, 2008-2013
    • Figure 4.14 Market Share (%) for Top 5 Erectile Dysfunction Treatments, 2007
    • Figure 4.15 World Revenues ($m) for Xalatan/Xalacom, 2008-2013
    • Figure 4.16 Market Share (%) for Top 5 Intraocular Treatments, 2007
    • Figure 4.17 World Revenues ($m) for Detrusitol, 2008-2013
    • Figure 4.18 Market Share (%) for Top 5 Urinary Incontinence Treatments, 2007
    • Figure 4.19 World Revenues ($m) for Zeldox/Geodon, 2008-2013
    • Figure 4.20 Market Share (%) for Top 5 Antipsychotic Drugs, 2007
    • Figure 4.21 World Revenues ($m) for Camptosar, 2008-2013
    • Figure 4.22 Market Share (%) for Top 5 Vinca Alkaloid Drugs, 2007
    • Figure 6.1 Market Share (%) of Pfizer's Pharma Sales by Region, 2007
    • Figure 6.2 Market Share (%) of Pfizer's Pharma Sales by Leading Country, 2007
    • Figure 6.3 Market Share (%) of Pfizer's Pharma Sales by Leading Country, 2010
    • Figure 6.4 Market Share (%) of Pfizer's Pharma Sales by Leading Country, 2013
    • Figure 6.5 Revenues of Pfizer's Pharma Sales ($m) by Leading Country, 2007, 2010 and 2013
    • Figure 7.1 Revenues ($m) of Pfizer's Animal Health Division, 2003-2007
    • Figure 7.2 Market Share (%) of Pfizer's Business Division, 2003
    • Figure 7.3 Market Share (%) of Pfizer's Business Division, 2005
    • Figure 7.4 Market Share (%) of Pfizer's Business Division, 2007
  • Companies Listed
    • Abbott
    • Abraxis Pharmaceutical
    • Alcatel-Lucent
    • Alcon
    • Allergan
    • Astellas
    • AstraZeneca
    • Barr
    • Bayer
    • Boehringer Ingelheim
    • Bovigen
    • Bristol-Myers Squibb
    • Cardinal Health
    • Catapult Genetics
    • Celldex Therapeutics
    • Chiron
    • Chugai Pharmaceutical
    • Coley Pharmaceuticals
    • CovX
    • Dainippon Sumitomo
    • Dr Reddy's Laboratories
    • Eli Lilly
    • Esperion Therapeutics
    • FivePrime Therapeutics
    • Genentech
    • GSK
    • HPIC
    • Johnson & Johnson
    • Ligand Pharmaceuticals
    • Medicare
    • Merck & Co
    • Mylan
    • Novartis
    • Otsuka
    • Pfizer
    • Pharmacia
    • Pharmacopoeia
    • PowderMed
    • Prasco Labs
    • Roche
    • Sanofi-Aventis
    • Schering Plough
    • Schwarz Pharma AG
    • Teva
    • UCB
    • Vicuron
    • Warner-Lambert